RE: RE: Shire's Markus Krenzlin pmrider, I certainly agree with you. Anecdotes we have mentioned point to an epic struggle to deliver large molecules across the BBB. If p97 can succeed in doing this in a safe manner we will witness ushering in of a new era in treating various CNS disorders.
As an investor my reward potential is staggering. We're talking about a company with a market cap of close to $40M. GSK paid Angiochem $31.5M up-front, plus the cost of research and potential royalty payments, to use their engineered peptide enabled compound to treat LSD. GSK has a further option to expand the use of the technology bringing the payment amount to $300M plus future royalties. There are hundreds of other applications.
So what is my potential reward on BTI...nobody knows really..A 10 bagger ($400M mCap) will get us $12/share...
In conclusion, I think this is the best investment I've come across in a long time:
The management team has kept the dilution to a minimum (hats off to Rob). They have a massivly disruptive technology in a huge $100bn market, and we are in the most exciting period that a junior biotech company can be in. I've been in BTI since 2010, when transcend was still a secondary technology to cognitest (see my article from Nov 2010), and the company has continued to deliver month after month. P97 has surpassed all expectations to date, with Herceptin results probably being the greatest surprise of all. I've doubled my money on the story but I still think we're in the early days.
TB
technicalbuy.com